Craig Anthony Portell, MD
PRIMARY APPOINTMENT:
Assistant Professor, Medicine: Hematology and Oncology
CONTACT:
UVA Emily Couric Clinical Cancer Center
1240 Lee St
Charlottesville, VA 22903
Telephone: 434.924.9333
Fax: 434.244.7526
Email: cp4ys@virginia.edu
EDUCATION AND TRAINING:
- Primary: Saint Louis University School of Medicine
- Residency: Loyola University of Chicago
- Fellowships: Cleveland Clinic – Taussig Cancer Institute
RESEARCH INTERESTS:
Clinical trials in hematologic malignancies, including leukemias and lymphomas, with a special interest in determining optimal combinations and timing of targeted agents in B-cell leukemias and lymphomas.
RESEARCH SUMMARY:
Clinical trials in hematologic malignancies, including leukemias and lymphomas, with a special interest in determining optimal combinations and timing of targeted agents in B-cell leukemias and lymphomas.
SELECT PUBLICATIONS:
- Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA, Postibrutinib outcomes in patients with mantle cell lymphoma., 2016; Blood. 127(12) 1559-63. PMID: 26764355
- Wages NA, Conaway MR, Slingluff CL, Williams ME, Portell CA, Hwu P, Petroni GR, Recent developments in the implementation of novel designs for early-phase combination studies., 2015; Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 26(5) 1036-7. PMID: 25697216
- Foster LH, Portell CA, The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas., 2015; Current treatment options in oncology. 16(6) 28. PMID: 25975444
- Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW, Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype., 2014; Clinical lymphoma, myeloma & leukemia. 14(3) 203-10. PMID: 24417911
- Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A, Hsi ED, The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways., 2013; British journal of hematology. 163(1) 72-80. PMID: 23889282 | PMCID: PMC3784300
- Aronow ME, Portell CA, Sweetenham JW, Singh AD, Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes., 2013; Ophthalmology. 121(1) 334-41. PMID: 24144449
- Portell CA, Advani AS, Novel targeted therapies in acute lymphoblastic leukemia., 2013; Leukemia & lymphoma. 55(4) 737-48. PMID: 23841506
- Portell CA, Wenzell CM, Advani AS, Clinical and pharmacologic aspects of blinatumomab in treating B-cell acute lymphoblastic leukemia., 2013; Clinical pharmacology: advances and applications. 5(0) 5-11. PMID: 23671399 | PMCID: PMC3650887